New Data From Epratuzumab To Be Presented At EULAR 2013

MORRIS PLAINS, N.J., June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics , Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Immunomedics and UCB (Euronext Brussels:UCB), a global biopharmaceutical company with a focus on immunology treatment and research, will present new data for their investigational studies of epratuzumab in systemic lupus erythematosus (SLE) at the European League Against Rheumatism (EULAR) 2013 Congress to be held in Madrid, Spain, from June 12 – 15, 2013.

Epratuzumab is an investigational medicine in development for the treatment of SLE. It is the first monoclonal antibody targeting CD22, a B-cell-specific protein that regulates B-cell activity. 1,2 Epratuzumab is not licensed in SLE.

Following is a guide to the investigational studies of epratuzumab for SLE being presented as oral presentations or posters at EULAR.

1. [OP0118]: Epratuzumab Mediates BCR-Antigen Trogocytosis As Potential Mechanism Of Action In Systemic Lupus Erythematosus (SLE) Goldenberg, D. et al.
  • Date/Time: June 13, 2013; 1120; Room N118
  • Session Info: Oral, Scientific Session

2. [THU0045]: Epratuzumab, An Antibody Targeting CD22 On B Cells, Induces Phosphoprotein Changes Following B-Cell Receptor Activation In Vitro Lumb, S. et al.
  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Tour, Poster Area

3. [THU0277]: Epratuzumab: Sustained Safety Profile And Effect On Corticosteroid Use On Long-Term Treatment In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study (SL0008) Wallace, D. et al.
  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

4. [THU0272]: Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study (SL0008) Gordon, C. et al.
  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

5. [THU0286]: Immunologic Response To Long-Term Epratuzumab Treatment In SL0008, An Open-Label Longterm Extension Study In Patients With Moderate-To-Severe Systemic Lupus Erythematosus Strand, V. et al.
  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

6. [THU0029]: Epratuzumab Influences BCR Signalling On TLR9 Pre-Activated B Cells By Targeting CD22 Sieger, N. et al.
  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

References

1. Sanz I., Eun-Hyung Lee F. B cells as therapeutic targets in SLE. Rheumatology; Vol. 6. 2010; Pp 326-327.

If you liked this article you might like

Kite Takeover by Gilead Lifts Biotech Stocks

Biotech Movers: Immunomedics, Aerie, Exelixis

Immunomedics, Seattle Genetics Scrap License Deal

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Bullish and Bearish Reversals for This Week